Moein Dehbashi
Overview
Explore the profile of Moein Dehbashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sadeghi N, Shirazi N, Dehbashi M, Maleki B, Cho W, Hojati Z
Pract Lab Med
. 2024 Nov;
42:e00437.
PMID: 39553462
Introduction: In response to the rapid spread of the SARS-CoV-2 virus, we developed a rapid molecular approach to diagnose COVID-19 without the need for RNA extraction. Methods: The study utilized...
2.
Moazeny M, Dehbashi M, Hojati Z, Esmaeili F
Mol Biol Rep
. 2022 Dec;
50(3):2183-2194.
PMID: 36565416
Background: As an available cell line, mouse pluripotent P19 has been widely employed for neuronal differentiation studies. In this research, by applying the in vitro differentiation of this cell line...
3.
Helaoui A, Sfar S, Boudhiba N, Dehghanian F, Dehbashi M, Bouchahda H, et al.
Mol Biol Rep
. 2022 Nov;
50(2):949-959.
PMID: 36376536
Background: Host genetic characteristics and environmental factors interactions may play a crucial role in cervical carcinogenesis. We investigated the impact of functional genetic variants of four xenobiotic-metabolizing genes (AhR, CYP1A1,...
4.
Heydari M, Hojati Z, Dehbashi M
Cell J
. 2021 Jun;
23(2):211-217.
PMID: 34096222
Objective: Alzheimer's disease (AD) is a type of dementia. Currently, there are not any existing and reliable methods for the prognosis or diagnosis of AD. Hence, finding a diagnostic/prognostic biomarker...
5.
Dehbashi M, Hojati Z, Motovali-Bashi M, Ganjalikhany M, Cho W, Shimosaka A, et al.
Front Oncol
. 2021 May;
11:649710.
PMID: 34055618
For many years, high-affinity subunit of IL-2 receptor (CD25) has been considered as a promising therapeutic target for different pathologic conditions like allograft rejection, autoimmunity, and cancers. Although CD25 is...
6.
Navabi P, Ganjalikhany M, Jafari S, Dehbashi M, Ganjalikhani-Hakemi M
Iran J Basic Med Sci
. 2021 May;
24(3):360-368.
PMID: 33995947
Objectives: IL-2Rα plays a critical role in maintaining immune function. However, expression and secretion of CD25 in various malignant disorders and autoimmune diseases are now well established. Thus, CD25 is...
7.
Dehbashi M, Hojati Z, Motovali-Bashi M, Ganjalikhani-Hakemi M, Shimosaka A, Cho W
Biol Chem
. 2021 Feb;
402(2):167-178.
PMID: 33544473
Cancer recurrence presents a huge challenge in cancer patient management. Immune escape is a key mechanism of cancer progression and metastatic dissemination. CD25 is expressed in regulatory T (Treg) cells...
8.
Hojati Z, Omidi F, Dehbashi M, Mohammad Soltani B
Iran Biomed J
. 2020 Nov;
25(1):62-7.
PMID: 33129241
No abstract available.
9.
Eslami A, Dehbashi M, Ashja-Arvan M, Salehi H, Azimzadeh M, Ganjalikhani-Hakemi M
Cytotechnology
. 2020 Sep;
72(5):773-784.
PMID: 32935166
Adipose-derived stem cells (ADSCs) are a type of mesenchymal stem cells with the therapeutic effects that make them one of the best sources for cell therapy. In this study, we...
10.
Hojati Z, Ganjalikhani-Hakemi M, Ameri M, Alimohammadi-Jelodar S, Dehbashi M, Mohammad Ganji M, et al.
Indian J Clin Biochem
. 2020 Jul;
35(3):359-366.
PMID: 32647415
Acute myelogenous leukemia (AML) is a complex blood malignancy leading to immature leukemic stem cells (LSCs) proliferation. T cell immunoglobulin mucin-3 (TIM-3) is known as a biomarker of AML LSCs....